Guest Editorial: Understanding of MPN and MDS/MPN based on molecular pathogenesis and clinical aspects

被引：0
|
作者：
Harada, Hironori [1 ]
机构：
[1] Tokyo Univ Pharm & Life Sci, Hachioji, Tokyo, Japan
来源：
INTERNATIONAL JOURNAL OF HEMATOLOGY | 2017年 / 105卷 / 06期
关键词：
MUTATIONS;
D O I：
10.1007/s12185-017-2244-y
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：709 / 710
页数：2
相关论文
共 50 条
  • [31] Coexisting driver mutations in MPN: clinical and molecular characteristics of a series of 11 patients
    De Roeck, L.
    Michaux, L.
    Debackere, K.
    Lierman, E.
    Vandenberghe, P.
    Devos, T.
    HEMATOLOGY, 2018, 23 (10) : 785 - 792
  • [32] IMPROVING OUTCOMES IN MDS/MPN: TREOSULFAN-BASED CONDITIONING FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
    Bruno, Alessandro
    Lazzari, Lorenzo
    Diral, Elisa
    Mastaglio, Sara
    Clerici, Daniela
    Marktel, Sarah
    Lunghi, Francesca
    Piemontese, Simona
    Sannipoli, Daniele
    Gariazzo, Camilla
    Scorpio, Gianluca
    Bergonzi, Gregorio
    Corti, Consuelo
    Carrabba, Matteo Giovanni
    Bernardi, Massimo
    Vago, Luca
    Lupo-Stanghellini, Teresa
    Ciceri, Fabio
    Peccatori, Jacopo
    Greco, Raffaella
    BONE MARROW TRANSPLANTATION, 2024, 59 : 248 - 248
  • [33] Increase in incidence of a type of leukemia transformed from MDS/MPN: A population-based study in Nagasaki, Japan
    Iwanaga, M.
    Soda, M.
    Miyazaki, Y.
    LEUKEMIA RESEARCH, 2013, 37 : S139 - S139
  • [34] Philadelphia-Negative MPN: A Molecular Journey, from Hematopoietic Stem Cell to Clinical Features
    Giai, Valentina
    Secreto, Carolina
    Freilone, Roberto
    Pregno, Patrizia
    MEDICINA-LITHUANIA, 2021, 57 (10):
  • [35] High Molecular Risk Marker (HMR) mutations in Myeloproliferative Neoplasms (MPN) - is it time for clinical implementation?
    Doehner, K.
    Stegelmann, F.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 269 - 269
  • [36] Guest editorial for signal processing aspects of molecular communications
    Atakan, Baris
    Galmes, Sebastia
    Haselmayr, Werner
    Farsad, Nariman
    Nakano, Tadashi
    DIGITAL SIGNAL PROCESSING, 2022, 124
  • [37] EZH2 Protein Expression Is Decreased in MDS and MDS/MPN and Correlated with EZH2 Mutation Status, Chromosomal 7 Abnormalities and Clinical Outcome
    Mcgraw, Kathy L.
    Nguyen, Johnny
    Alali, Najla
    Song, Jinming
    Sallman, David
    Padron, Eric
    Lancet, Jeffrey E.
    Qin, Daihui
    Epling-Burnette, P. K.
    Moscinski, Lynn C.
    Komrokji, Rami S.
    List, Alan F.
    Zhang, Ling
    BLOOD, 2016, 128 (22)
  • [38] A New Clinically-Based Subclassification Proposal in CMML with Significant Prognostic Implications to Overcome the MDS/MPN Categorizing Dilemma
    Onida, Francesco
    Iacobelli, Simona
    Garcia-Manero, Guillermo
    Patnaik, Mrinal M.
    Itzykson, Raphael
    Lasho, Terra L.
    Nazha, Aziz
    Rampal, Raajit K.
    Sanchez, Matias Eugenio
    Jabbour, Elias J.
    Al Ali, Najla H.
    Thompson, Zachary
    Colla, Simona
    Fenaux, Pierre
    Kantarjian, Hagop M.
    Killick, Sally
    Mikkael, Sekeres A.
    List, Alan F.
    Komrokji, Rami S.
    Tefferi, Ayalew
    Solary, Eric
    Padron, Eric
    BLOOD, 2016, 128 (22)
  • [39] Elucidation of Additional Mutations By Next-Generation Sequencing Is of Clinical Significance in Patients with Rare MPNs and MDS/MPN Overlap Syndromes
    Kirschner, Martin M. J.
    Schemionek, Mirle
    Begemann, Matthias
    Isfort, Susanne
    Feldberg, Kristina
    Brummendorf, Tim H.
    Koschmieder, Steffen
    BLOOD, 2016, 128 (22)
  • [40] Validation of Molecular International Prognostic Scoring System (IPSS-M) in myelodysplastic/myeloproliferative neoplasms, not otherwise specified (MDS/MPN-NOS)
    Mangaonkar, Abhishek A.
    Swoboda, David M.
    Lasho, Terra L.
    Finke, Christy
    Ketterling, Rhett P.
    Reichard, Kaaren K.
    Komrokji, Rami
    Padron, Eric
    Patnaik, Mrinal M.
    LEUKEMIA RESEARCH, 2023, 131
12345